ARCALIS, Inc.

About ARCALIS, Inc.

ARCALIS is a CDMO specializing in mRNA medicines and vaccines, founded by Axcelead, Japan’s first drug discovery platform, and Arcturus Therapeutics, a US mRNA company. In 2023, ARCALIS opened a GMP mRNA drug substance facility in Japan. In 2024, we achieved the world's first commercial production of a self-amplifying mRNA COVID-19 vaccine. We support clients from early research to commercial prod...

  • Country/Region:
    Japan
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
Contact info

Products from ARCALIS, Inc. (2)

  • GMP Manufacturing Services for mRNA and LNP

    Product GMP Manufacturing Services for mRNA and LNP

    ARCALIS provides GMP-compliant manufacturing of mRNA and LNP formulation services, including commercial-scale production. With its facilities in Minamisoma, Japan, ARCALIS supports flexible batch sizes, technology transfer, and regulatory documentation. Notably, ARCALIS was selected as the manufacturin...
  • Non-GMP mRNA Development & CMC Services

    Product Non-GMP mRNA Development & CMC Services

    ARCALIS provides a fully integrated, end-to-end R&D support service for early-stage mRNA drug discovery. The service includes sequence design with proprietary AI-driven codon optimization algorithms, mRNA manufacturing, LNP formulation, and evaluation using in vitro/in vivo studies. 

ARCALIS, Inc. Resources (1)

  • Video ARCALIS's Corporate Short Film

    Who is ARCALIS? Take a quick look into our world—where science meets innovation to create next-generation mRNA medicines. This short film gives you a glimpse of our people, passion, and progress in revolutionizing drug manufacturing.